Latest news
Rocket Pharmaceuticals Reports Positive Safety Update for RP-A501 Under Modified Phase 2 Protocol in Danon Disease - BioPharm InternationalBioPharm International · Mon, 03 Aug 2026 17:07:07 GMTRocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease - Business WireBusiness Wire · Mon, 03 Aug 2026 11:00:00 GMTRocket Pharmaceuticals Provides Positive Clinical Safety Update from Initial Three Patients Treated with Rp-A501 Under Modified Phase 2 Protocol for Danon Disease - marketscreener.commarketscreener.com · Mon, 03 Aug 2026 11:00:00 GMTClearmind Announces Positive Safety Findings for CMND 100, Demonstrating Consistent Tolerability Throughout Full Dose Escalation in Part A of its FDA-Regulated Clinical Trial - The Manila TimesThe Manila Times · Thu, 30 Jul 2026 07:00:00 GMTT.N. approves governance framework for ensuring patient safety, positive experience - The HinduThe Hindu · Tue, 28 Jul 2026 07:00:00 GMT